A Phase I/IIa Study to Evaluate Safety and Immunogenicity of Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Adult Healthy Volunteers
Latest Information Update: 18 Oct 2023
At a glance
- Drugs PHH-1V (Primary) ; Tozinameran
- Indications COVID 2019 infections
- Focus Adverse reactions; First in man
- Sponsors LABORATORIOS HIPRA
- 28 Feb 2023 Status changed from active, no longer recruiting to completed.
- 15 Feb 2022 Planned End Date changed from 1 Sep 2022 to 30 Sep 2022.
- 22 Sep 2021 Status changed from recruiting to active, no longer recruiting.